Literature DB >> 8361190

Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease.

H Komai1, I T Adatia, M J Elliott, M R de Leval, S G Haworth.   

Abstract

The plasma level of the potent vasoconstrictor endothelin-1 was measured in children who underwent cardiac operations. Forty-five patients were divided into two groups, those with a high pulmonary blood flow (HF group; n = 23) and those with a normal or low flow (NF group; n = 22). Seven blood samples were taken: immediately before cardiopulmonary bypass, immediately after removing the aortic cross-clamps, immediately after discontinuing bypass, and at 20 minutes and 3, 6, and 24 hours after termination of bypass. The plasma levels of endothelin-1 were similar in both groups before bypass. From the time the aortic crossclamps were removed, the plasma endothelin-1 levels in both groups increased significantly, to reach a peak level at 3 to 6 hours. The increase was significantly greater in the HF than in the NF group, and the maximum values in the two groups were 12.6 +/- 1.1 and 9.6 +/- 0.8 fmol/ml, respectively (mean +/- standard error of the mean, p < 0.05). The value 20 minutes after bypass showed a positive correlation with the mean pulmonary arterial pressure measured at the preoperative cardiac catheterization study (r = 0.41, p < 0.05). In addition, a significant positive correlation was obtained between endothelin-1 3 hours after bypass and the maximum pulmonary/systemic arterial pressure ratio during the first 12 hours after operation (r = 0.86, p < 0.05). These results suggest that cardiopulmonary bypass is associated with an immediate postoperative increase in circulating endothelin and that patients who had a high pulmonary blood flow before the operation are particularly vulnerable, bypass having a more injurious effect on a lung with preexisting endothelial dysfunction. A high level of circulating endothelin may predispose to pulmonary vascular lability and pulmonary hypertensive crises in the postoperative period.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361190

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Potential role of endothelin receptor antagonists in the setting of cardiopulmonary bypass: relevance to myocardial performance.

Authors:  A Ergul; C Joffs; A C Walker; F G Spinale
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  Surgical strategies for patients with congenital heart disease and severe pulmonary hypertension in low/middle-income countries.

Authors:  Sachin Talwar; Vikas Kumar Keshri; Shiv Kumar Choudhary; Saurabh Kumar Gupta; Sivasubramanian Ramakrishnan; Rajnish Juneja; Anita Saxena; Shyam Sunder Kothari; Balram Airan
Journal:  Heart Asia       Date:  2015-10-09

3.  Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery.

Authors:  B Prendergast; D E Newby; L E Wilson; D J Webb; P S Mankad
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

4.  Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus.

Authors:  D D Ivy; T A Parker; J W Ziegler; H L Galan; J P Kinsella; R M Tuder; S H Abman
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

Review 5.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

6.  Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt.

Authors:  I Adatia; S E Barrow; P D Stratton; J M Ritter; S G Haworth
Journal:  Br Heart J       Date:  1994-11

7.  Aprotinin attenuates the elevation of pulmonary vascular resistance after cardiopulmonary bypass.

Authors:  Tae-Jin Yun; Joon-Ryang Rho
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

8.  Mechanical forces alter endothelin-1 signaling: comparative ovine models of congenital heart disease.

Authors:  Terry Zhu; Samuel Chiacchia; Rebecca J Kameny; Antoni Garcia De Herreros; Wenhui Gong; Gary W Raff; Jason B Boehme; Emin Maltepe; Juan C Lasheras; Stephen M Black; Sanjeev A Datar; Jeffrey R Fineman
Journal:  Pulm Circ       Date:  2020-05-14       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.